AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02098928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand-acupuncture
Description: Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
Study NCT02098928 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrico-acupuncture
Description: Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
Study NCT02098928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrico-acupuncture
Description: Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposome-encapsulated irinotecan hydrochloride PEP02
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT01375816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT00729911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation ablation
Description: Radio-frequency catheter ablation of atrial fibrillation
Study NCT00729911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Taken orally on a daily basis.
Study NCT00330980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Pravastatin (Pravachol)
Description: Participants will receive 40 mg of pravastatin for 6 months.
Study NCT00330980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg Simvastatin
Description: Participants will receive 20 mg of simvastatin for 6 months.
Study NCT00330980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 6 months.
Study NCT02693080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPP-Seq
Description: Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
Study NCT02693080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-200
Description: Contrast agent
Study NCT02693080 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Study NCT03356353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: 20 mg tablets
Study NCT00615693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study NCT02704949 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1/4 fluoroscopy dose
Description: Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
Study NCT02704949 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Full-dose
Description: Use of full fluoroscopy dose while ureteroscopy is being performed
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Pembrolizumab
Description: The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~* Pembrolizumab (200 mg intravenous infusion \[IV\])~* N-803 (15 μg/kg subcutaneously \[SC\])
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab
Description: The treatment plan in the experimental arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV)~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)~Day 8:~* Nab-paclitaxel (100mg/m² IV)~Day 15:~* Nab-paclitaxel (100mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Description: The treatment plan in the experimental arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~* N-803 (15 μg/kg SC)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)~* N-803 (15 μg/kg SC)
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab
Description: The treatment plan in the control arm of Cohort B will consist of an induction period of repeated 3-week cycles for 4 cycles then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Carboplatin (up to 900mg IV)~* Nab-paclitaxel (100mg/m² IV) or Paclitaxel (200mg/m² IV)~* Pembrolizumab (200mg IV)~Day 8:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Day 15:~* Nab-paclitaxel (100mg/m² IV) -if assigned to receive~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
Description: The treatment plan in the control arm of Cohort C will consist of an induction period with repeated 3-week cycles for 4 cycles, then a maintenance period of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Induction (4 cycles):~Day 1, every 3 weeks:~* Cisplatin (75mg/m²) or Carboplatin (up to 900mg IV)~* Pembrolizumab (200mg IV)~* Pemetrexed (500mg/m² IV)~Maintenance:~Day 1, every 3 weeks:~* Pembrolizumab (200mg IV)
Study NCT03520686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab
Description: The treatment plan for the experimental arm of Cohort D will consist of repeated 6-week cycles for a maximum of 18 cycles (approximately 2 years). Nab-paclitaxel and Carboplatin will only be administered in cycle 1.
Study NCT00834600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan, hydrochlorothiazide, amlodipine
Description: hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
Study NCT00834600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan, hydrochlorothiazide, amlodipine
Description: hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
Study NCT00834600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) or olmesartan
Description: HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
Study NCT00834600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) or olmesartan
Description: HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
Study NCT02585986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: daily intake of 1 capsule probiotic
Study NCT02585986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily intake of 1 capsule containing placebo
Study NCT03861416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine 1.4% 500 ml
Description: Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Study NCT03861416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine 1.4% 250 ml + placebo 250 ml
Description: Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
Study NCT03861416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Study NCT03777046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
Study NCT03777046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC with Psychology Therapy (CBT)
Description: Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
Study NCT02188940 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Dietary
Description: The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
Study NCT02188940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
Study NCT02188940 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education Program
Description: The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
Study NCT02188940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Program
Description: The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
Study NCT02188940 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral Therapy
Description: The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
Study NCT02188940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Therapy
Description: The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
Study NCT02188940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
Study NCT02188940 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching and Breathing exercise
Description: Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups.
Study NCT00000401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral bovine type II collagen
Description: Drug can be interrupted or stopped for suspected adverse events.
Study NCT01864681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and Metformin
Description: Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
Study NCT01864681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib and placebo
Description: Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
Study NCT02860234 — intervention group
Intervention type: DRUG
Intervention: Oxaliplatin
Study NCT02860234 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Study NCT02860234 — intervention group
Intervention type: RADIATION
Intervention: intensity modulated radiotherapy
Study NCT02860234 — intervention group
Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA
Study NCT02860234 — intervention group
Intervention type: PROCEDURE
Intervention: Nonoperative Management
Study NCT02860234 — intervention group
Intervention type: PROCEDURE
Intervention: Local Excision
Study NCT02860234 — intervention group
Intervention type: PROCEDURE
Intervention: Total Mesorectal Excision
Study NCT02860234 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Study NCT04277481 — intervention group
Intervention type: OTHER
Intervention: 10 minute cold pack
Description: 10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
Study NCT04277481 — intervention group
Intervention type: OTHER
Intervention: 12 minute cold pack
Description: 12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
Study NCT04277481 — intervention group
Intervention type: OTHER
Intervention: 15 minute cold pack
Description: 15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
Study NCT04277481 — intervention group
Intervention type: OTHER
Intervention: 20 minute cold pack
Description: 20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
Study NCT02919891 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires
Study NCT00595881 — intervention group
Intervention type: DEVICE
Intervention: Bedside emergency ultrasound
Description: Ultrasound will be performed on the lesion in question.
Study NCT01481714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate, magnesium oxid and citric acid
Description: * A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation
Study NCT01481714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate/magnesium oxide and citric acid
Description: The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am.
Study NCT00374062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation therapy 1
Description: relaxation therapy 1
Study NCT00374062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation therapy 2
Description: relaxation therapy 2
Study NCT00374062 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: relaxation therapy 3
Description: relaxation therapy 3
Study NCT02409264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homeopathic Remedy
Description: Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
Study NCT01289561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol + Caffeine Beverage
Description: 14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Study NCT01289561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol + Caffeine-placebo
Description: 14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Study NCT03988894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mDASHNa App
Description: The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
Study NCT00562536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping
Description: Delay of umbilical cord clamping 30 to 45 seconds
Study NCT03960385 — intervention group
Intervention type: BIOLOGICAL
Intervention: CYD-TDV
Description: Dengue vaccine
Study NCT02319564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Study NCT02319564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone and Salbutamol
Study NCT02319564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02319564 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerochamber Max®
Study NCT02319564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerochamber Max®
Study NCT04198311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
Study NCT03593005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure